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Human LANCL2, also known as Testis-specific Adriamycin Sensitivity Protein (TASP), is a member of the highly conserved and widely
distributed lanthionine synthetase component C-like (LANCL) protein family. Expression studies of tagged LANCL2 revealed the major
localization to the plasma membrane, juxta-nuclear vesicles, and the nucleus, in contrast to the homologue LANCL1 that was mainly found in the
cytosol and nucleus. We identified the unique N-terminus of LANCL2 to function as the membrane anchor and characterized the relevant N-
terminal myristoylation and a basic phosphatidylinositol phosphate-binding site. Interestingly, the non-myristoylated protein was confined to the
nucleus indicating that the myristoylation targets LANCL2 to the plasma membrane. Cholesterol depletion by methyl-β-cyclodextrin caused the
partial dissociation of overexpressed LANCL2 from the plasma membrane in vitro, whereas in vivo we observed an enhanced cell detachment
from the matrix. We found that overexpressed LANCL2 interacts with the cortical actin cytoskeleton and therefore may play a role in cytoskeleton
reorganization and in consequence to cell detachment. Moreover, we confirmed previous data that LANCL2 overexpression enhances the cellular
sensitivity to the anticancer drug adriamycin and found that this sensitivity is dependent on the myristoylation and membrane association of
LANCL2.
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The eukaryotic LanC-like (LANCL) protein family is widely
distributed in animals, plants, and microorganisms, and shows aAbbreviations: BSA, bovine serum albumin; DOPC, 1,2-Dioleoyl-sn-
glycero-3-phosphocholine; DMEM, Dulbecco's modified Eagle's medium;
GFP, green fluorescent protein; GST, glutathione-S-transferase; HMA, 2-
hydroxy myristic acid; LANCL2, lanthionine synthetase component C-like 2;
LANCL2-GFP del., N-terminal truncation of C-terminally GFP-tagged
LANCL2; LANCL2-GFP mutG1A, C-terminally GFP-tagged LANCL2 with
glycine-1 mutated to alanine; mβCD, methyl-β-cyclodextrin; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PBS, phosphate-buf-
fered saline; P-gp, P-glycoprotein; PI, phosphatidylinositol; PIP, phosphatidy-
linositol phosphate(s); PMSF, phenylmethylsulfonyl fluoride; RT, room
temperature; TASP, Testis-specific Adriamycin Sensitivity Protein; TBS, Tris-
buffered saline; TNET, Tris–NaCl–EDTA–Triton X-100
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doi:10.1016/j.bbamem.2006.07.018clear structural similarity to the prokaryotic lanthionine
synthetase component C (LanC) proteins [1]. These LanC pro-
teins are involved in the synthesis of lanthionine-containing
antimicrobial peptides known as lantibiotics [2]. Because
lantibiotics have not been found in higher eukaryotes, it is
likely that LanC-like proteins have different function(s). Very
recently, it was suggested that LANCL proteins might catalyze
the posttranslational modification of cysteine residues due to
their structural similarity to farnesyl transferase [3].
The first member of the family, LANCL1, was isolated from
human erythrocyte membranes and the primary structure was
determined [4]. Due to seven predicted hydrophobic α-helices in
this protein, a function as a G protein coupled receptor was
proposed and the gene termed GPR69A. By analogy, the
LANCL2 gene was termed GPR69B. Subsequently, detailed
immunochemical data revealed that the LANCL1 protein is not
an integral but a loosely bound peripheral membrane protein in
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G protein coupled receptors. The real function of these proteins
is currently unknown.
The human genome contains three LANCL genes, LANCL1
on chromosome 2 [5], LANCL2 on chromosome 7 [6], and
LANCL3 on the X chromosome. Northern blot and dot blot
analyses of LANCL1 and LANCL2 mRNA in human tissues
revealed similar expression patterns with strong expression in
various regions of the brain and in testis and weak ubiquitous
expression in other tissues [4,7]. LANCL2 mRNA has been
isolated and identified in a screen for genes whose down-
regulation results in anticancer drug resistance and was
therefore also termed Testis-specific Adriamycin Sensitivity
Protein (TASP, GenBank accession no. AB035966). Accord-
ingly, Park et al. showed that overexpressed LANCL2
sensitizes cells to the anticancer drug adriamycin due to
down-regulation of the multi drug resistance protein, P-
glycoprotein (P-gp), concluding a regulatory transcriptional
activity for LANCL2 [8].
Amino acid sequence comparison of LANCL2 with the other
human LANCL proteins shows a similarity of 75% (LANCL1)
and 47% (LANCL3). LANCL2 contains 15 cysteine residues,
three of which are conserved in all human LANCL proteins and
8 are conserved between LANCL2 and LANCL1 (Fig. 1).
Interestingly, the N-terminus of LANCL2 differs from the other
LANCL proteins by an N-terminal extension of 17 amino acid
residues and an insertion of 19 residues (Fig. 1).Fig. 1. Multiple alignment of the human LANCL proteins. The amino acid sequences
highlighted by dark grey background, whereas similar residues are shown as light grey
and the insertion of 19 residues are marked in yellow. The N-terminal glycine residu
cluster is boxed. hLANCL1: Swissprot accession number O89112, hLANCL2: S
AAH93667.In this study, we characterized LANCL2 as a plasma mem-
brane associated protein that is N-myristoylated and contains a
phosphatidylinositol phosphate (PIP) binding site at the N-
terminus. We showed that LANCL2 is associated with the
cortical actin cytoskeleton and that overexpression enhances cell
detachment upon cholesterol depletion. LANCL2 myristoyla-
tion is essential for the membrane association and cellular
sensitivity to the anticancer drug adriamycin.
2. Materials and methods
2.1. Drugs and chemicals
[9,10-3H]-Myristic acid was purchased from Moravek Biochemicals Inc.
(Brea, CA), D-myo-phosphatidylinositol phosphates: PI, PI(3)P, PI(4)P, PI(5)P
were fromEchelon (Salt Lake City, UT), 1,2-dioleoyl-sn-glycero-3-phosphocho-
line (DOPC), adriamycin/doxorubicin, 2-hydroxytetradecanoic acid/2-hydro-
xymyristic acid (HMA), digitonin, filipin III, methyl-β-cyclodextrin (mβCD),
cytochalasin B, cytochalasin D, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were from Sigma. Purified LANCL1 was a kind gift
of Hemma Bauer.
2.2. Antibodies
Monoclonal antibodies used in this study were anti-GFP (Santa Cruz), anti-
GST (Amersham, Uppsala, Sweden), anti-β actin (Sigma), anti-annexin II
(Transduction Laboratories, Lexington, KY) and anti-stomatin GARP-50 as
described previously [9]. The polyclonal rabbit anti-GFP antibodywas purchased
fromAbCam (Cambridge, UK) and the polyclonal rabbit anti-LANCL2 antibody
1434 was produced by Sigma-Genosys (Haverhill, Suffolk, UK) against the N-were aligned by CLUSTALWand shaded by BOXSHADE. Identical residues are
boxes. Cysteine residues are boxed in red. The extended N-terminus of LANCL2
e, a putative myristoylation site, is marked in blue, and an N-terminal polybasic
wissprot accession number Q9NS86, hLANCL3: GenBank accession number
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protein KLH. This antibody was purified by peptide affinity chromatography
using standard procedures. The rabbit polyclonal anti-LANCL1 antibody H60
was described previously [1]. Alexa-conjugated secondary antibodies were
obtained from Molecular Probes (Leiden, The Netherlands).
2.3. Cell line and growth conditions
Human epithelial cells of amniotic origin (UAC) were maintained in
Dulbecco's modified Eagle's medium (DMEM) (PAA Laboratories, Linz,
Austria) supplemented with 10% fetal calf serum (PAA) and antibiotics
(100 units/ml penicillin and streptomycin) under standard conditions, as
described [10].
2.4. Plasmid constructs and mutagenesis
The cDNA of LANCL2 is commercially available as an EST-clone from
HGMP Resource Centre (IMAGE number: 50715) that was cloned into the
lafmid vector at the restriction sites NotI and HindIII. This vector served as
template for PCR amplification to subclone LANCL2 into the pEGFP-N3 vector
usingHindIII andKpnI as restriction sites. The plasmid pEGFP-N3 (Clontech) is
a eukaryotic expression vector containing an SV40 origin, a cytomegalovirus
promoter, neomycin (G418) selectionmarker, and codes for the green fluorescent
protein (GFP). This vector was used to create the LANCL2-GFP fusion protein
with the GFP-tag fused to the C-terminus.
LANCL2 cDNAs coding for the wild-type protein and the N-terminal
truncation of 17 amino acids (LANCL2-GFP del.1–17) were generated by PCR
and cloned into the unique restriction site HindIII and KpnI of pEGFP-N3.
Furthermore, a site-directed mutation of LANCL2, glycine to alanine at position
1 (LANCL2-GFP mutG1A), was generated and cloned into the pEGFP-N3
vector. A Kozak consensus translation initiation site was inserted at the N-
terminus of each construct to further increase the translation efficiency in
eukaryotic cells. The LANCL1-GFP construct was a kind gift of Hemma Bauer.
For the expression and purification of LANCL2 using the Bac-to-Bac®
baculovirus expression system (Invitrogen), LANCL2 was fused to a GST-tag at
the N-terminus. The pGEX-4T vector was used as template for PCR to amplify
the GST-tag with its thrombin cleavage site. LANCL2 was amplified from the
lafmid vector with a 5′ extension of five alanines, the thrombin site, and a
glycine–alanine–glycine linker. The GST-tag was linked to the 5′ end of
LANCL2 by a third PCR resulting in a GST-LANCL2 fusion construct. This
construct was used for the Bac-to-Bac® system and subsequently cloned into the
pFastBac1 vector (Invitrogen) according to the manufacturer's protocol.
2.5. Expression of GST-LANCL2 and purification of the tagged and
untagged LANCL2
For expression of GST-LANCL2, Sf9 cells and the Bac-to-Bac® system of
Invitrogen were used. The cells were infected according to the manufacturer's
protocol. 96 h post-infection, the cells were lysed in phosphate-buffered saline
(PBS), pH 7.4, 10 mM DTT, 1 mM EDTA, 0.1% saponine, containing
proteinase inhibitors for 20 min at room temperature (RT). Cell debris was
removed by centrifugation for 1 h at 65,000×g at 4 °C and the GST-LANCL2 in
the supernatant was affinity-purified by GSH Sepharose™ 4B (Amersham). The
protein was eluted by TBS, pH 8.0 supplemented with 20 mM glutathione. In
order to gain purified LANCL2 without the GST-tag, the GSH affinity-bound
GST-LANCL2 was cleaved by thrombin in Tris-buffered saline (TBS), pH 8.0,
5 mM DTT. Subsequently, thrombin was removed by Benzamidine-Sepharose
6B (Amersham). To concentrate the purified protein, Amicon Ultra 10 MWCO
tubes (Millipore, Carrigtwohill, Ireland) were used.
2.6. Stable transfection of UAC cells
Cells were grown and transfected with LANCL2-GFP or LANCL2-GFP
mutG1A by means of Lipofectamine (Invitrogen) according to the manufac-
turer's protocol. Within a time period of 2–3 weeks, LANCL2-GFP positive
clones formed and were raised. The selecting antibiotic G418 was always
supplemented to maintain stable transfection.2.7. 3H-Myristate cell labeling and immunoprecipitation
UAC cells stably expressing LANCL2-GFP were grown in 100 mm dishes
and incubated with 4 ml of DMEM, 2% dialyzed fetal calf serum (PAA) for 1 h.
One plate was labeled with [9,10-3H]-myristic acid at 60 μCi/ml by incubation
in 5 ml serum-free medium for 4 h at 37 °C. After incubation, the cells were
rinsed twice with PBS, lysed in 1 ml of TNET (20 mMTris–Cl, pH 8.0, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100) containing 1 μg/ml pepstatin, 10 μg/ml
leupeptin, 10 μg/ml aprotinin, 1 mM PMSF, and 5% fetal calf serum, for 10 min
at RT. To remove insoluble material, the lysates were centrifuged for 10 min at
15,000×g and 4 °C. The extracts were pre-incubated for 1 h with 30 μl of either
anti-rabbit or anti-mouse IgG-agarose beads (Sigma) and cleared by
centrifugation. For specific precipitation, 30 μl of either anti-rabbit or anti-
mouse IgG-agarose were incubated with 1 μg rabbit anti-GFP antibody
(Invitrogen) or 1 μg of the negative control mouse antibody GARP-52,
respectively, in TNET for 2 h with gentle agitation. The beads were pelleted,
washed 3 times with TNET, mixed with the pre-cleaned lysates supplemented
with 1 mg/ml bovine serum albumin (BSA), and incubated for 2 h at 4 °C. The
beads were washed 4 times with 4 volumes TNETand eluted with 150 μl of 1.5×
Laemmli sample buffer for 1 h at RT. The samples were then separated by SDS-
PAGE, gels were treated with Amplify (Amersham) according to the
manufacturer's instructions, and dried. BioMax MS films (Kodak) were
exposed for 10 days at −80 °C.
2.8. Membrane preparation and cholesterol depletion
Cells were grown to confluence on a 150 mm dish, subsequently rinsed
twice with cold PBS, scraped, and resuspended in 2 ml cold homogenization
buffer (10 mM Tris–Hepes, pH 7.4, 30 mM mannitol, 10 mM CaCl2, 1 μg/ml
pepstatin, 10 μg/ml leupeptin, 10 μg/ml aprotinin, 1 mM PMSF). The cell
suspension was transferred to a chilled Dounce homogenizer and dounced 100
times. The cell lysate was transferred to a Corex tube, centrifuged for 10 min at
4000×g at 4 °C, and the supernatant was removed and ultracentrifuged for
30 min at 65,000×g at 4 °C. The membrane pellet was then resuspended in
10 mMTris–Hepes, pH 7.4, 150 mMNaCl, and aliquots were treated with either
15 mM mβCD, 10 μg/ml filipin, or 0.01% digitonin, for 15 min at 4 °C. After
incubation, the membranes were pelleted by ultracentrifugation for 30 min at
200,000×g and 4 °C.
2.9. Liposome assay
DOPC alone or mixed with PI, PI(3)P, PI(4)P or PI(5)P, respectively, in
molar ratios of 25:1 was made up in 95% chloroform/5% methanol and dried
under a stream of argon [11]. The lipid film was further dried for 1 h under high
vacuum and resuspended in 100 μl rehydration buffer (250 mM raffinose,
25 mM HEPES pH 7.4, 1 mM DTT) by vortexing. 300 μl of binding buffer
(100 mM sorbitol, 40 mM HEPES pH 7.4, 1 mM DTT, 130 mM KCl, 0.5 mM
MgCl2) were added and the sample was sonicated for 1 min at low power in
order to obtain small liposome vesicles. The liposomes were pelleted for 10 min
at 70,000×g. The pellet was resuspended in binding buffer to a final lipid
concentration of 6 mM. 25 μl of liposomes and 0.5 μg of protein (GST-
LANCL2) were mixed in binding buffer to give a final volume of 100 μl. The
lipid–protein mixture was incubated for 1 h at RT. Then the sample was
centrifuged for 10 min at 70,000×g, the supernatant was removed and the pellet
washed with 100 μl of binding buffer. The pellet was analyzed by SDS-PAGE
and Western blotting.
2.10. SDS-PAGE and Western blot analysis
Proteins were analyzed by 11% SDS-PAGE. For Western blotting, proteins
were electrotransferred to nitrocellulose by standard methods along with the Pre-
stained Protein Molecular Weight Marker (Fermentas, St. Leon-Rot, Germany).
Filters were blocked by 3% (w/v) dry milk in 10 mM Tris–Cl, pH 8.0, 150 mM
NaCl, 0.1% (v/v) Tween 20 (TBS-Tween) for 1 h, followed by incubation with
primary antibody in TBS-Tween for 1 h at RT. The commercial antibodies were
used according to the manufacturer's instructions. Goat anti-mouse and goat
anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Sigma)
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SuperSignal™ chemiluminescent substrate (Pierce).
2.11. PIP Strip analyses
The PIPMicro Strips™ (Echelon, Salt Lake City, UT) were blocked with 3%
(w/v) fatty acid-free BSA in TBS-Tween by gently agitating for 1 h at RT.
Subsequently, the strips were incubated with either 0.5 μg/ml of purified
LANCL2, GST-LANCL2, the LANCL2 N-terminal peptide GETMS-
KRLKLHLGG, the negative control protein LANCL1, or the positive control
reagent for PIP Strips, recombinant LL5-α domain GST-tagged protein
(MultiPIP Grip™, Echelon) for 1–4 h in TBS-Tween. The membranes were
rinsed 3×5 min in TBS-Tween. The bound proteins were detected by incubation
with the primary antibodies (anti-GST for GST-LANCL2 and MultiPIP Grip™,
anti-LANCL2 1434 for LANCL2 and the N-terminal peptide, and H60 antibody
for LANCL1), the corresponding secondary antibodies, HRP-conjugated anti-
mouse and anti-rabbit IgG (Sigma), and the SuperSignal™ chemiluminescent
substrate (Pierce).
2.12. Detachment assay
Cells expressing wild-type or mutant LANCL2 were seeded on 6-well plates
on the day before the experiment. The nearly confluent cells were treated with
15 mMmβCD for 20 min. After the incubation, the loosely associated cells were
3 times flushed with a gentle stream of a pipette. The supernatants containing the
detached cells were removed and particles of 10–30 μm diameter were counted
by means of a cell counter (Z™ Series Coulter Counter®, Beckman). The
remaining adherent cells were trypsinized and the cell number of these cell
suspensions was also measured by the Coulter counter. The percentage of
detached cells after treatment with mβCD was calculated.
2.13. Cell proliferation assay
Different transfected clones were plated at a density of 8000 cells/well in a
96-well plate and cultured under standard conditions. After incubation
overnight, adriamycin was added to the cultures to give final concentrations
of 0, 250, 1000, 2000, 4000, and 8000 nM. Cells were grown in the presence of
the drug for 3 days, and subsequently an MTT assay was performed. The
medium was removed from each well, and 100 μl of fresh medium and 10 μl of
MTT dye (5 mg/ml stock solution in PBS) were added to each well. Cells were
incubated with MTT for 6 h, after which the blue formazan crystals were
dissolved in 0.1 N HCl, 2-propanol (100 μl per well). Within 30 min after
dissolving the crystals, the sample absorbances were determined at 570 nm using
a microplate reader (Labsystems Multiskan RC, Life Science, UK).
2.14. Confocal fluorescence microscopy
Stably or transiently transfected UAC cells were grown on cover slips under
standard conditions. For some experiments, cells were treated with cytochalasin
B or cytochalasin D, at a concentration of 0.5 μg/ml for 2 h or with 10 μMHMA
for 24 h. The cells were fixed in freshly prepared 3% (w/v) paraformaldehyde in
PBS. To stain nucleoli, the monoclonal antibody 3G4B2 was used and detected
by Alexa Fluor® 594 goat anti-mouse IgG antibody. Actin filaments were
stained with rhodamine–phalloidin according to the manufacturer's protocol
(Molecular Probes). The cover slips were mounted with Vectashield (Vector
Laboratories, Burlingame, CA). Images were collected using a confocal
microscope (TCSNT, Leica) and the corresponding software.Fig. 2. Different localization of LANCL1-GFP and LANCL2-GFP. UAC cells
were (A) transiently transfected with LANCL1-GFP or (B) stably transfected
with LANCL2-GFP. The cells were fixed and analyzed by confocal fluorescence
microscopy. Bars=10 μm (A, B).3. Results
3.1. LANCL2 is a membrane associated protein
To study the subcellular localization of LANCL2 compared
to LANCL1, we transfected the human cell line UAC with
LANCL1-GFP and LANCL2-GFP, respectively, and visualizedthe expressed proteins by fluorescence microscopy. Immuno-
fluorescence data of the endogenous LANCL2 protein were not
reliable because of the low expression level of this protein and
the low specificity of the LANCL2 antibody in immunocyto-
chemical applications. LANCL2-GFP strongly localized to the
plasma membrane and juxta-nuclear vesicles that partially co-
localized with the late endosomal markers Lamp1 and
Lysotracker (data not shown), whereas LANCL1-GFP was
absent from the plasma membrane and exclusively found in the
cytosol and nucleus (Fig. 2). The expression of the respective
myc-tagged proteins showed the same localization (data not
shown). The different localization raised the question whether
the membrane association of LANCL2 is caused by the specific
N-terminal region, containing an N-terminal glycine residue
and a polybasic stretch, or palmitoylation of one or more
cysteine residues not conserved in LANCL1 (Fig. 1). We
constructed an N-terminal deletion starting at position 18
(LANCL2-GFP del.1–17) with a conserved methionine residue
equivalent to the start methionine of LANCL1 (Fig. 1). The
stable expression of this construct was analyzed by fluorescence
microscopy and revealed the expression in the cytosol and
nucleus, but not at the plasma membrane or the juxta-nuclear
pool (data not shown), indicating that the N-terminus is crucial
for the membrane-association.
3.2. N-Myristoylation of LANCL2 is crucial for the membrane
association
To study the relevance of the N-terminal glycine residue as a
putative myristoylation site, we mutated this glycine to an
alanine. After the stable transfection of UAC cells with this
LANCL2-GFP mutG1A construct we observed the localization
by confocal fluorescence microscopy. LANCL2-GFP mutG1A
was not associated with the plasma membrane but localized
almost exclusively to the nucleus, particularly to the nucleoli
(Fig. 3A). The same result was obtained when we treated cells
stably expressing wild-type LANCL2-GFP with 2-hydroxy-
myristic acid (HMA), an inhibitor of N-myristoyltransferases
[12,13] (Fig. 3B). These data strongly suggest that the
myristoylation of LANCL2 is essential for membrane-associa-
tion. To confirm the incorporation of myristate into the protein,
stably expressing LANCL2-GFP cells were metabolically
Fig. 3. LANCL2 is an N-myristoylated protein and interference with this
myristoylation leads to nuclear localization. (A) UAC cells stably expressing the
non-myristoylated LANCL2-GFP mutG1Awere fixed and analyzed by confocal
fluorescence microscopy. (B) UAC cells stably expressing wild type LANCL2-
GFP were incubated with 10 μM HMA, an inhibitor of N-myristoyltransferase,
for 24 h. (C) UAC cells stably expressing LANCL2-GFP were metabolically
labeled with 3H-myristic acid for 4 h. The cells were lysed in 1% TX-100 and
immunoprecipitation was performed. LANCL2-GFP was precipitated by the
polyclonal anti-GFP antibody. The irrelevant antibody GARP-52 served as
negative control. The precipitates of both antibodies (P) and the supernatant
(SN) of the anti-GFP precipitation were analyzed by SDS-PAGE, autoradio-
graphy (upper panel), and Western blotting (lower panel). Bars=10 μm (A, B).
Fig. 4. LANCL2 binds to PIPs, particularly the monophosphates. (A) PIP Micro
Strips™ (Echelon) were blockedwith 3% fatty acid-free BSA and incubatedwith
0.5 μg/ml LANCL2, GST-LANCL2, the N-terminal peptide GETMS-
KRLKLHLGG, the positive control reagent that recognizes all PIPs, the GST-
tagged LL5-α PH domain, and the negative control LANCL1 for 3 h at RT.
LANCL2 and the N-terminal peptide were detected by the anti-LANCL2
antibody 1434, LANCL1by theH60 antibody, whereas GST-LANCL2 andGST-
LL5-α were detected by the anti-GST antibody. The lipids spotted on the PIP
Micro Strips™ on the left side are: lysophosphatidic acid (LPA), lysopho-
sphatidylcholine (LPC), phosphatidylinositol (PI), phosphatidylinositol-3-phos-
phate (PI(3)P), phosphatidylinositol-4-phosphate (PI(4)P), phosphatidylinositol-
5-phosphate (PI(5)P), phosphatidylcholine (PC), phosphatidylethanolamine
(PE); on the right side: sphingosine-1-phosphate (S1P), phosphatidylinositol-
3,4-bisphosphate (PI(3,4)P2), phosphatidylinositol-3,5-bisphosphate (PI(3,5)
P2), phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), phosphatidylinositol-
3,4,5-trisphosphate (PI(3,4,5)P3), phosphatidic acid (PA), phosphatidylserine
(PS), blank. (B) Liposomes were generated from DOPCmixtures with PI(3)P, PI
(4)P, PI(5)P, and PI, respectively, in a molar ratio 1:25 (PIPs/DOPC). The small
liposome vesicleswere incubatedwith 0.5 μg of purifiedGST-LANCL2 for 1 h at
RT. Additionally, 0.5 μg GST-LANCL2 were incubated without liposomes in
order to exclude protein precipitation. The liposomes together with the affinity-
bound protein were pelleted by ultracentrifugation and analyzed by Western
blotting.
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was immunoprecipitated with an anti-GFP antibody. As
expected, the autoradiogram showed a band corresponding to
LANCL2-GFP labeled with 3H-myristic acid (Fig. 3C). The
immunoprecipitation was specific because no signal was found
in the negative control with an irrelevant antibody (Fig. 3C).
3.3. PIP-binding as an additional membrane attachment of
LANCL2
Due to the limited hydrophobicity of the myristoyl anchor,
additional membrane attachment factors may be required for
enhanced membrane targeting [14]. Because the LANCL2
sequence does not contain a cysteine residue nearby the N-
terminal glycine for palmitoylation (Fig. 1), we focused on the
N-terminal polybasic region KRLKLH (Fig. 1, boxed residues
6–11) of LANCL2 that could possibly interact with negatively
charged phospholipids, particularly PIPs. Therefore, we
incubated PIP Strips™ (Echelon) with the purified
LANCL2, the GST-LANCL2 fusion protein, the LANCL2
N-terminal peptide GETMSKRLKLHLGG (residues 1–14),
and a positive control reagent for PIP Strips, the recombinant
LL5-α domain GST-tagged protein, respectively. The GST-
tagged proteins were detected with the anti-GST antibody,
whereas LANCL2 and the N-terminal peptide were identifiedby the anti-LANCL2 antibody that recognizes the N-terminus.
LANCL2 and the GST-tagged LANCL2 showed a specific
interaction with PI monophosphates, and a faint reaction with
other PIPs (Fig. 4A). The N-terminal peptide alone was
sufficient to recognize PIPs, particularly the PI(5)P and to a
lesser extent the other PIPs and phosphatidic acid (PA) (Fig. 4A).
The LL5-α domain showed a strong interaction with all PIPs.
whereas the homologous protein LANCL1 that does not contain
Fig. 5. Membrane association of LANCL2 and attachment of LANCL2
overexpressing cells is cholesterol-dependent. (A) Membranes of LANCL2-
GFP expressing cells were prepared and treated for 15 min at 4 °C with either
15 mM mβCD, 10 μg/ml filipin, or 0.01% digitonin. The membranes (P) were
pelleted by ultracentrifugation and resuspended in the same volume as the
supernatants (SN). Aliquots of both were analyzed by Western blotting as
indicated. (B) UAC cells stably transfected with either LANCL2-GFP,
LANCL2-GFP mutG1A, or GFP alone, were treated with 15 mM mβCD.
After 30 min incubation, the number of detached cells was determined. The
diagram shows the mean values of three independent experiments.
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(Fig. 4A). In order to study the association of LANCL2 with PI
monophosphates by another method, we established a liposome
binding assay. DOPC liposomes enriched with different PI
monophosphates were incubated with purified GST-LANCL2,
washed and pelleted, and the associated protein was detected by
immunoblotting. A strong association of LANCL2 with PI(3)P
and PI(5)P liposomes was observed, whereas the binding to PI
(4)P liposomes was not significantly higher than to pure DOPC
liposomes (Fig. 4B). As a control, GST-LANCL2 was incubated
without liposomes to check whether protein precipitation occurs
during the procedure. From these data we conclude that the non-
homologous N-terminal basic region of LANCL2 contains a
PIP-binding domain that is probably enhancing the membrane
binding of LANCL2.
3.4. Cholesterol depletion of LANCL2 expressing cells causes
membrane dissociation of LANCL2 in vitro and cell
detachment in vivo
It has previously been shown that the PIP2-binding,
peripheral membrane protein annexin II is specifically released
by sequestration of membrane cholesterol [15,16].
To address the question whether the membrane cholesterol
level also affects the membrane association of LANCL2, we
performed cholesterol extraction experiments on isolated
membranes. We prepared membranes of LANCL2 expressing
cells and incubated these with the cholesterol sequestrating
agents, digitonin, filipin, and mβCD. Digitonin had the
greatest effect and released about 50% of the membrane-
bound LANCL2-GFP and about 50%of the membrane-associated
actin. As described previously [16], annexin II was completely
released from the membrane (Fig. 5A) whereas the integral
membrane protein stomatin remained on the membrane indicating
that the membranes were not solubilized by the digitonin
treatment. These data show that the membrane association of
LANCL2 is influenced by themembrane cholesterol level and that
actin displays a similar behavior in this respect.
To investigate the effect of cholesterol depletion on the
subcellular distribution of LANCL2, we treated cells stably
expressing LANCL2-GFP with mβCD. We noticed that the
plasma membrane association of LANCL2-GFP remained
unchanged (data not shown) but the cells easily detached from
thematrix. A cell detachment assay showed that about 40%of the
LANCL2-GFP expressing cells were released into the super-
natant. To study the impact of LANCL2 myristoylation on the
cell detachment, we performed the same assay with cells stably
expressing the non-myristoylated mutant LANCL2-GFP
mutG1A. The extent of detachment of the non-myristoylated
mutant and the GFP control was 3% and 9%, respectively,
indicating that myristoylation and membrane localization of
LANCL2 is necessary for the observed cell detachment (Fig. 5B).
3.5. Association of LANCL2 with the cortical actin cytoskeleton
The enhanced detachment of LANCL2 expressing cells
suggested that LANCL2 is involved in the reorganization of theactin cytoskeleton and/or assembly of focal adhesions. There-
fore, we performed fluorescence microscopy studies of
LANCL2-GFP and actin that was visualized by rhodamine–
phalloidin. LANCL2-GFP showed a striking co-localization
with actin at the plasma membrane particularly the membrane
protrusions (Fig. 6). To test the relevance of this co-localization,
we incubated LANCL2-GFP expressing cells with the actin
depolymerizing drugs, cytochalasin B and D. Again, we
observed a strong co-localization, however, not equally
distributed at the plasma membrane but in large aggregates
that were predominantly found at blebbing sites (Fig. 6). It is to
mention that cell membrane blebbing is a known phenomenon
observed upon cytochalasin treatment. The co-localization data
suggest a direct or indirect association of LANCL2 with the
cortical actin cytoskeleton.
3.6. Overexpression of myristoylated LANCL2 increases
cellular adriamycin sensitivity
Overexpressed LANCL2 has been found to sensitize MES-
SA cells to the anticancer drug adriamycin [8]. Therefore, we
examined whether UAC cells overexpressing LANCL2 were
similarly sensitive to adriamycin treatment. Cells were incubated
Fig. 6. Co-localization of LANCL2-GFP and actin. (A) UAC cells stably expressing LANCL2-GFP were stained with rhodamine-phalloidin (red) for the localization
of actin filaments. Confocal images of LANCL2-GFP and actin are shown. (B and C) The LANCL2-GFP expressing cells were treated with (B) cytochalasin B
(0.5 μg/ml) or (C) cytochalasin D (0.5 μ g/ml) for 2 h prior to fixation and staining with phalloidin. Bars = 10 μ m (A, B, C).
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viability was assessed by a proliferation assay. In GFP
expressing cells, a rise of proliferation was observed at low
concentrations of adriamycin and a decrease at concentrations
higher than 700 nM (Fig. 7). In contrast, LANCL2-GFP
expressing cells showed a continuous decrease in cell viabilityFig. 7. Myristoylation of LANCL2 is essential for increased cellular sensitivity to
adriamycin. UAC cells stably transfected with either LANCL2-GFP, the non-
myristoylated LANCL2-GFP mutG1A, or GFP alone, were treated with various
concentrations (0, 250, 1000, 2000, 4000, 8000 nM) of adriamycin. Cells were
grown in the presence of the drug for 3 days and subsequently a proliferation
assay was performed. 100% survival refers to the proliferation rate of untreated
cells. Themean values of five independent representative experiments are shown.in proportion to adriamycin concentrations starting at 125 nM.
At a concentration of 1 μMadriamycin, the GFP expressing cells
were still resistant and proliferated at a rate of 100% (compared
to untreated GFP expressing cells), whereas the viability of
LANCL2-GFP expressing cells was clearly diminished to 77%
relative to untreated LANCL2-GFP cells (Fig. 7). To test
whether the membrane association of LANCL2 is essential for
this enhanced adriamycin susceptibility, we treated the non-
myristoylated mutant LANCL2-GFP mutG1A with the same
adriamycin concentrations. Interestingly, LANCL2-GFP
mutG1A expressing cells did not show a decreased viability
(Fig. 7) indicating that the membrane association of LANCL2 is
important for the increased cellular adriamycin sensitivity.
4. Discussion
In this study we show that the closely related proteins
LANCL1 and LANCL2 (Fig. 1) display a different subcellular
localization. Whereas LANCL1 is mainly a cytosolic and
nuclear protein, a major part of LANCL2 is associated with the
plasma membrane and juxta-nuclear vesicles that co-localize
with the late endosomal markers Lamp1 and Lysotracker (data
not shown). A minor part of LANCL2 is also present in the
nucleus (Fig. 2). The membrane association is mediated by the
LANCL2-specific N-terminal region which contains a
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membrane localization of LANCL2 is completely abolished
by the treatment of the cells with the N-myristoyltransferase
inhibitor HMA or when myristoylation is prevented by mutation
(LANCL2-GFP mutG1A), this modification is essential for
plasma membrane targeting of LANCL2. The non-myristoy-
lated LANCL2 is found exclusively in the nucleus, particularly
in nucleoli (Fig. 3).
It is known that myristoylated proteins have diverse
biological functions in signal transduction under normal and
pathological conditions [17,18]. N-myristoylation, which is
a rare protein modification (http://mendel.imp.univie.ac.at/
myristate/myrbase/), usually occurs co-translationally but post-
translational myristoylation has also been reported [19,20].
David-Pfeuty et al. showed that myristoylation of pp60src
regulates the functional localization and activity of this protein
[21]. The authors suggest that myristoylation might prevent
unregulated nuclear transport of proteins whose non-myristoy-
lated counterparts are readily moved into the nucleus. This form
of regulation might also apply to LANCL2.
Our biochemical data revealed that the N-terminal region of
LANCL2 contains a PIP-bindingmotif with the polybasic region
KRLKLH most probably representing the interacting site.
LANCL2 preferentially interacts with PI monophosphates
(Fig. 4). Apart from their function as signaling molecules,
PIPs are known asmediators of the actin cytoskeletonmembrane
association [22,23]. Specifically, the redistribution of plasma
membrane PI(4,5)P2 results in the reorganization of the cyto-
skeleton [22] and PI(5)P has been shown to be involved in
cortical actin polymerization [23]. Cholesterol depletion affects
the level of PI(4,5)P2 in the plasma membrane and thereby the
membrane-associated cytoskeletal organization [22]. LANCL2
was released from isolated plasma membranes upon incubation
with various cholesterol-depleting or -binding drugs together
with components of the cortical cytoskeleton, actin and annexin
II (Fig. 5A). It is conceivable that the cholesterol depletion
interferes with the interaction between LANCL2 and PIPs
thereby impairing the second membrane anchor of LANCL2.
These data indicate that myristoylation and PIP-binding is
crucial for high membrane affinity of LANCL2.
The co-localization of LANCL2 and actin at the plasma
membrane and in large patches upon cytochalasin treatment
suggests a close connection of LANCL2 to the cortical cyto-
skeleton (Fig. 6). Interestingly, cholesterol depletion of cells
expressing the wild type LANCL2 but not the non-myristoylated
mutant revealed enhanced cell detachment (Fig. 5B). Similarly, a
myristoylation-dependent regulation of cell adhesion has been
reported for theMARCKS proteins [24]. Membrane association of
LANCL2 might have a regulatory function on the cortical
cytoskeleton and thereby influence the cholesterol-dependent cell
adhesion. However, more detailed analyses are needed to elucidate
the mutual effects of myristoylation, PIP-binding, and membrane
cholesterol levels on themembrane association of LANCL2 and its
possible role in cortical cytoskeleton organization.
Park et al. reported that LANCL2 increases the sensitivity of
MES-SA cells to the anticancer drug adriamycin by transcrip-
tional suppression of the multi drug resistance protein P-gp [8].Our respective data using LANCL2 overexpressing UAC cells
(Fig. 7) confirm these results, however, the underlying me-
chanism appears to be different in this cell system. First, the
UAC cells do not contain detectable amounts of P-gp (data not
shown), and second, we observed that the enhancement of
cellular sensitivity to adriamycin is critically dependent on the
myristoylation of LANCL2 (Fig. 7). LANCL2 may be involved
in a signaling pathway where its membrane association is an
essential prerequisite. Several other myristoylated proteins have
been shown to act as signaling components at the membrane
[14]. It is also conceivable that a corresponding signaling
pathway leads to the translocation of LANCL2 to the nucleus
where it may exert the postulated transcriptional activity [8].
Alternatively, the increased sensitivity of LANCL2 overexpres-
sing cells may be due to a regulatory effect on the cortical
cytoskeleton dynamics or multi drug transport processes at the
plasma membrane.
In this study, we have shown that LANCL2 is a novel
myristoylated PIP-binding membrane protein that is found in
association with the cortical actin cytoskeleton interfering with
cell attachment in a cholesterol-dependent manner. Moreover,
we have shown that LANCL2 increases the cellular adriamycin
sensitivity only in the myristoylated and membrane-bound
form. Further studies will have to clarify in detail how this
protein is involved in these diverse processes.
Acknowledgments
This work was supported by grant number P15786 from the
Austrian Science Fund (FWF).
We are grateful to Hemma Bauer for the LANCL1-GFP
construct, purified LANCL1, advice, and discussions.
References
[1] H. Bauer, H. Mayer, A. Marchler-Bauer, U. Salzer, R. Prohaska, Charac-
terization of p40/GPR69A as a peripheral membrane protein related to the
lantibiotic synthetase component C, Biochem. Biophys. Res. Commun.
275 (2000) 69–74.
[2] H.G. Sahl, G. Bierbaum, Lantibiotics: biosynthesis and biological activities
of uniquely modified peptides from gram-positive bacteria, Annu. Rev.
Microbiol. 52 (1998) 41–79.
[3] B. Li, J.P. Yu, J.S. Brunzelle, G.N. Moll, W.A. van der Donk, S.K. Nair,
Structure and mechanism of the lantibiotic cyclase involved in nisin
biosynthesis, Science 311 (2006) 1464–1467.
[4] H. Mayer, U. Salzer, J. Breuss, S. Ziegler, A. Marchler-Bauer, R. Prohaska,
Isolation, molecular characterization, and tissue-specific expression of a
novel putative G protein-coupled receptor, Biochim. Biophys. Acta 1395
(1998) 301–308.
[5] H. Mayer, H. Bauer, R. Prohaska, Organization and chromosomal
localization of the human and mouse genes coding for LanC-like protein
1 (LANCL1), Cytogenet. Cell Genet. 93 (2001) 100–104.
[6] M. Katoh, Identification and characterization of human ZPBP-like gene in
silico, Int. J. Mol. Med. 12 (2003) 399–404.
[7] H. Mayer, M. Pongratz, R. Prohaska, Molecular cloning, characterization,
and tissue-specific expression of human LANCL2, a novel member of the
LanC-like protein family, DNA Seq. 12 (2001) 161–166.
[8] S. Park, C.D. James, Lanthionine synthetase components C-like 2
increases cellular sensitivity to adriamycin by decreasing the expression
of P-glycoprotein through a transcription-mediated mechanism, Cancer
Res. 63 (2003) 723–727.
1767C. Landlinger et al. / Biochimica et Biophysica Acta 1758 (2006) 1759–1767[9] C.M. Hiebl-Dirschmied, G.R. Adolf, R. Prohaska, Isolation and partial
characterization of the human erythrocyte band 7 integral membrane
protein, Biochim. Biophys. Acta 1065 (1991) 195–202.
[10] L. Snyers, E. Umlauf, R. Prohaska, Oligomeric nature of the integral
membrane protein stomatin, J. Biol. Chem. 273 (1998) 17221–17226.
[11] M.J. Hayes, C.J. Merrifield, D. Shao, J. Ayala-Sanmartin, C.D. Schorey,
T.P. Levine, J. Proust, J. Curran, M. Bailly, S.E. Moss, Annexin 2 binding
to phosphatidylinositol 4,5-bisphosphate on endocytic vesicles is
regulated by the stress response pathway, J. Biol. Chem. 279 (2004)
14157–14164.
[12] L.A. Paige, G.Q. Zheng, S.A. DeFrees, J.M. Cassady, R.L. Geahlen,
Metabolic activation of 2-substituted derivatives of myristic acid to form
potent inhibitors of myristoyl CoA:protein N-myristoyltransferase,
Biochemistry 29 (1990) 10566–10873.
[13] F. Galbiati, F. Guzzi, A.I. Magee, G. Milligan, M. Parenti, Chemical
inhibition of myristoylation of the G-protein Gi1 alpha by 2-hydroxymyr-
istate does not interfere with its palmitoylation or membrane association.
Evidence that palmitoylation, but not myristoylation, regulates membrane
attachment, Biochem. J. 313 (Pt 3) (1996) 717–720.
[14] S. Maurer-Stroh, F. Eisenhaber, Myristoylation of viral and bacterial
proteins, Trends Microbiol. 12 (2004) 178–185.
[15] N.A. Gokhale, A. Abraham, M.A. Digman, E. Gratton, W. Cho,
Phosphoinositide specificity of and mechanism of lipid domain
formation by annexin A2-p11 heterotetramer, J. Biol. Chem. 280
(2005) 42831–42840.[16] T. Harder, R. Kellner, R.G. Parton, J. Gruenberg, Specific release of
membrane-bound annexin II and cortical cytoskeletal elements by
sequestration of membrane cholesterol, Mol. Biol. Cell 8 (1997) 533–545.
[17] J.A. Boutin, Myristoylation, Cell. Signal. 9 (1997) 15–35.
[18] T.A. Farazi, G. Waksman, J.I. Gordon, The biology and enzymology of
protein N-myristoylation, J. Biol. Chem. 276 (2001) 39501–39504.
[19] M.J. King, R.K. Sharma, N-myristoyl transferase assay using phospho-
cellulose paper binding, Anal. Biochem. 199 (1991) 149–153.
[20] A.M. da Silva, C. Klein, A rapid posttranslational myristoylation of a 68-
kD protein in D. discoideum, J. Cell Biol. 111 (1990) 401–407.
[21] T. David-Pfeuty, S. Bagrodia, D. Shalloway, Differential localization
patterns of myristoylated and nonmyristoylated c-Src proteins in
interphase and mitotic c-Src overexpresser cells, J. Cell Sci. 105 (Pt 3)
(1993) 613–628.
[22] J. Kwik, S. Boyle, D. Fooksman, L. Margolis, M.P. Sheetz, M. Edidin,
Membrane cholesterol, lateral mobility, and the phosphatidylinositol 4,5-
bisphosphate-dependent organization of cell actin, Proc. Natl. Acad. Sci.
U. S. A. 100 (2003) 13964–13969.
[23] D. Sbrissa, O.C. Ikonomov, J. Strakova, A. Shisheva, Role for a novel
signaling intermediate, phosphatidylinositol 5-phosphate, in insulin-
regulated F-actin stress fiber breakdown and GLUT4 translocation,
Endocrinology 145 (2004) 4853–4865.
[24] G. Spizz, P.J. Blackshear, Overexpression of the myristoylated alanine-rich
C-kinase substrate inhibits cell adhesion to extracellular matrix compo-
nents, J. Biol. Chem. 276 (2001) 32264–32273.
